Article Details
Retrieved on: 2024-04-18 01:24:18
Tags for this article:
Click the tags to see associated articles and topics
Summary
Tirzepatide, a biotechnology product by Eli Lilly and Company, demonstrated up to 63% reduction in the apnea-hypopnea index for sleep apnea, indicating significant improvement for sleep disorders like obstructive sleep apnea.
Article found on: investor.lilly.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here